UDCA & METHOTREXATE FOR PRIMARY BILIARY CIRRHOSIS

UDCA

• 批准号: 7377596
• 负责人: MARLYN J MAYO
• 金额: $ 2.54万
• 依托单位: UT SOUTHWESTERN MEDICAL CENTER
• 依托单位国家: 美国
• 财政年份: 2006
• 资助国家: 美国
• 起止时间: 2006-04-01 至 2007-03-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7377596
• 关键词: UDCA; METHOTREXATE; PRIMARY; BILIARY; CIRRHOSIS

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. Primary biliary cirrhosis (PBC) is a disease of unknown cause in which the small bile ducts in the liver are destroyed slowly by inflammation. Most physicians believe that PBC is due to an abnormal immune response directed against the bile ducts in the liver. It is considered to be an autoimmune disease. Loss of bile ducts causes bile to back up in the liver and ultimately leads to liver damage, liver cirrhosis and possibly liver failure. There is no known specific treatment for PBC at present. UDCA and methotrexate may be useful in the treatment of this autoimmune disease. This study will examine whether treatment with UDCA and methotrexate is better than treatment with UDCA alone.

该子项目是利用NIH/NCRR资助的中心赠款提供的资源的许多研究子项目之一。子弹和调查员（PI）可能已经从其他NIH来源获得了主要资金，因此可以在其他清晰的条目中代表。列出的机构适用于该中心，这不一定是调查员的机构。原发性胆道肝硬化（PBC）是一种未知原因的疾病，其中肝脏中的小胆管因炎症缓慢破坏。大多数医生认为PBC是由于针对肝脏中胆管的异常免疫反应引起的。它被认为是一种自身免疫性疾病。胆管的损失导致胆汁在肝脏中备份，并最终导致肝脏损伤，肝硬化和可能导致肝衰竭。 目前尚无针对PBC的特定治疗方法。 UDCA和甲氨蝶呤可能对治疗这种自身免疫性疾病有用。这项研究将检查使用UDCA和甲氨蝶呤治疗是否比单独使用UDCA治疗更好。